Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) Meeting Abstract

  

Authors:	Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
Abstract Title:	Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
Meeting Title:	42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	24
Issue:	18 Suppl. Pt. 1
Meeting Dates:	2006 Jun 2-6
Meeting Location:	Atlanta, GA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2006-06-01
Start Page:	244S
Language:	English
ACCESSION:	WOS:000239009401411
PROVIDER:	wos
DOI:	10.1200/jco.2006.24.18_suppl.4613
Notes:	--- - Meeting Abstract: 4613 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/32440